Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Spring;13(1):43-56.
doi: 10.1111/j.1527-3458.2007.00004.x.

Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data

Tim De Smedt  1 , Robrecht Raedt, Kristl Vonck, Paul Boon
Affiliations
Review

Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data

Tim De Smedt et al. CNS Drug Rev. 2007 Spring.

Abstract

The objective of this article was to review and summarize the available reports on the preclinical profile of the novel anticonvulsant drug levetiracetam (LEV). Therefore, a careful search was conducted in the MEDLINE database and combined with guidelines from regulatory agencies, proceedings of professional scientific meetings, and information provided by the manufacturers. This article provides detailed information on the anticonvulsant effects of LEV in various animal models of epilepsy and on its pharmacology in laboratory animals. The mechanism of action of LEV is reviewed, with special regard to its recently discovered binding site, the synaptic vesicle protein 2A. In general, LEV is shown to be a safe, broad-spectrum anticonvulsant drug with highly beneficial pharmacokinetic properties and a distinct mechanism of action. The clinical studies with LEV will be discussed in the second part of this review article to be published subsequently.

PubMed Disclaimer

References

    1. Angehagen M, Margineanu DG, Ben‐Menachem E, Ronnback L, Hansson E, Klitgaard H (2003) Levetiracetam reduces caffeine‐induced Ca2+ transients and epileptiform potentials in hippocampal neurons. Neuroreport 14:471‐475. - PubMed
    1. Benedetti MS, Coupez R, Whomsley R, Nicolas JM, Collart P, Baltes E (2004) Comparative pharmacokinetics and metabolism of levetiracetam, a new antiepileptic agent, in mouse, rat, rabbit, and dog. Xenobiotica 34:281‐300. - PubMed
    1. Birnstiel S, Wulfert E, Beck SG (1997) Levetiracetam (ucb L059) affects in vitro models of epilepsy in CA3 pyramidal neurons without altering normal synaptic transmission. N S Arch Pharmacol 356:611‐618. - PubMed
    1. Bittigau P, Sifringer M, Genz K, Reith E, Pospischil D, Govindarajalu S, Dzietko M, Pesditschek S, Mai I, Dikranian K, et al (2002) Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. PNAS 99:15089‐15094. - PMC - PubMed
    1. Bouwman BM, Van Rijn CM (2004) Effects of levetiracetam on spike and wave discharges in WAG/Rij rats. Seizure 13:591‐594. - PubMed

Publication types